NCT04302181View on ClinicalTrials.gov

Augmenting Massed Prolonged Exposure With a Stellate Ganglion Block to Treat PTSD

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

July 1, 2021

Study Completion Date

December 3, 2021

Conditions
Stress Disorders, Post-Traumatic
Interventions
DRUG

Ropivacaine injection

6.5cc of Ropivacaine HCl 0.5%, one time into the stellate ganglion

Trial Locations (2)

78229

University of Texas Health Science Center at San Antonio, San Antonio

78234

Brooke Army Medical Center, Fort Sam Houston

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT04302181 - Augmenting Massed Prolonged Exposure With a Stellate Ganglion Block to Treat PTSD | Biotech Hunter | Biotech Hunter